Merger Remedies in France (2026): Divestitures, Behavioural Commitments & Clearance Conditions

Merger remedies France sits at the centre of deal execution risk in 2026, as sustained scrutiny by the Autorité de la concurrence and increasingly overlapping foreign investment screening reshape how transactions are cleared and closed. For in-house counsel, private equity sponsors and deal lawyers, the ability to anticipate divestiture demands, structure behavioural commitments and translate regulator expectations into workable SPA language now determines whether a signed deal actually completes. This guide sets out the legal framework, the remedies toolbox, practical divestiture design, behavioural commitment drafting, clearance conditions and the interaction with FDI screening, all viewed through the lens of practitioners who must negotiate and document these outcomes.

The emphasis throughout is on execution: timing, trustee mechanics, sample SPA clauses and negotiation positions that hold up under scrutiny.

Executive Summary and 2026 Enforcement Snapshot

Deal teams entering the French market in 2026 face a demanding clearance environment. The Autorité de la concurrence has signalled a readiness to require substantive remedies where competitive concerns arise, and the parallel foreign investment regime administered by the French Ministry for the Economy and Finance adds a second layer of conditionality that must be sequenced carefully.

• Remedies are increasingly deal-shaping. Structural divestitures remain the regulator’s preferred fix for horizontal overlaps, and parties should budget for value leakage and carve-out complexity from the outset.
• Timing risk is real. Negotiating and implementing merger remedies France frequently extends the review timetable, and divestiture completion can run months beyond formal clearance.
• FDI and competition review interact. Where a transaction triggers both regimes, undertakings offered in one process must be reconciled with commitments in the other.
• SPA drafting is the safety net. Conditions precedent, trustee appointment mechanics, risk allocation and reverse break arrangements are where clearance risk is actually managed.

Will 2026 be a good year for M&A? The realistic answer for the French market is cautiously positive: deal activity remains healthy, but transactions with any material competitive dimension are more complex, slower and more dependent on well-designed remedies. The winners will be teams that plan for remedies negotiation France as a core workstream rather than an afterthought.

How French Merger Remedies Work: Legal Framework and Regulator Practice

Understanding merger remedies France begins with the statutory architecture that gives the regulator its powers and the division of competence between national and European review.

Statutory Basis Under the Code de commerce

French merger control is grounded in Book IV of the Code de commerce (in particular the provisions on the control of concentrations), which governs concentrations, notification thresholds, review procedures and the sanctions available for non-compliance. The relevant provisions establish the obligation to notify qualifying concentrations, the standstill obligation preventing implementation before clearance, and the Autorité de la concurrence’s authority to make clearance conditional on commitments or to prohibit a transaction outright. These statutory foundations, published on Légifrance, are the anchor for every remedy the Autorité imposes and for the enforceability of the commitments parties offer.

Crucially, the Code de commerce framework distinguishes between commitments proposed by the parties and injunctions or conditions the Autorité imposes. That distinction matters in practice: negotiated commitments generally give parties more control over drafting and timing, whereas imposed conditions can be more rigid. Structuring a deal so that the parties retain the initiative on remedy design is a recurring theme of effective merger control remedies France strategy.

Autorité de la concurrence Role and Remedies Toolbox

The Autorité de la concurrence assesses whether a concentration significantly impedes effective competition and, where it does, whether remedies can restore competitive conditions. Its remedies toolbox spans structural measures, behavioural commitments and hybrid packages that combine both. Structural remedies, chiefly divestitures, are favoured where a clean, durable removal of the competitive overlap is achievable. Behavioural remedies, such as access, supply or licensing commitments, are used where structural fixes are disproportionate or impracticable but ongoing conduct obligations can address the concern.

The Autorité also relies on trustees and monitoring mechanisms to give its remedies teeth. A monitoring trustee oversees compliance during implementation, while a divestiture trustee may be empowered to sell a business if the parties fail to do so within an agreed period. Autorité de la concurrence remedies practice consistently emphasises the durability and effectiveness of the fix, the identity and viability of any purchaser, and the ease of monitoring compliance.

EU Versus National Competence

Not every transaction affecting France is reviewed in Paris. Where a concentration has an EU dimension by reference to the turnover thresholds in Council Regulation (EC) No 139/2004 (the EU Merger Regulation), the European Commission has exclusive competence under the one-stop-shop principle, and remedies are negotiated in Brussels rather than with the Autorité. Deals below those thresholds but meeting French notification criteria fall to the Autorité. In some cases referral mechanisms allow cases to move between the Commission and national authorities. For deal teams, the practical point is jurisdictional certainty: identify early which regulator will design the remedy package, because the drafting conventions, timetables and precedent differ.

The interplay between the EU Merger Regulation and national review directly shapes how merger remedies France are conceived and documented.

Types of Remedies: What Regulators Ask For and Why

Remedies fall into recognisable categories, each with distinct commercial consequences and drafting requirements. Selecting the right structure, and negotiating its scope, is where value is preserved or lost.

Divestitures: Asset Sales and Business Carve-Outs

A divestiture France remedy requires the merged entity to sell a business, asset package or product line to an approved purchaser, thereby removing the competitive overlap. Divestitures are the regulator’s structural remedy of choice because they create a clean, permanent solution that requires little ongoing supervision. In practice, the divested business must be a viable standalone competitor, which drives complex questions about which contracts, employees, intellectual property, customer relationships and shared services must travel with it.

Carve-outs are rarely simple. Where the target business shares manufacturing, IT systems or distribution with the retained group, transitional service arrangements are needed to keep the divested business operating until it can stand alone. The scope of the divestiture, precisely which assets are included, is often the most contested element of remedies negotiation France, because over-inclusion destroys deal value while under-inclusion risks the Autorité rejecting the package as insufficient.

Behavioural Remedies: Access, Supply and Licensing

Behavioural remedies France impose ongoing conduct obligations rather than requiring a sale. Common examples include commitments to continue supplying inputs to downstream competitors on non-discriminatory terms, to grant access to essential infrastructure or platforms, or to license technology to preserve competition. These remedies are attractive to parties because they preserve the integrity of the acquired business, but regulators approach them with caution: they are harder to monitor, depend on sustained good-faith compliance, and can require supervision for years.

Effective behavioural commitments must be measurable. Vague undertakings to act “fairly” or “reasonably” invite disputes and enforcement difficulty. The best behavioural remedies specify objective benchmarks, reporting cadence, and consequences for breach, including, in serious cases, conversion to a structural remedy.

Structural Remedies Versus Hold-Separate

Between signing and divestiture completion, a hold-separate obligation may be imposed to preserve the competitive independence of the business earmarked for sale. Hold-separate arrangements keep the target operating as a distinct, viable and marketable entity, with independent management and ring-fenced information, preventing integration that would foreclose competition before the divestiture is achieved. The trade-off is operational friction and cost: running a business at arm’s length from its acquirer is inefficient and demands clear governance rules.

Trustee and Monitoring Arrangements

Independent trustees are central to modern merger remedies France. A monitoring trustee verifies that hold-separate and behavioural obligations are honoured and reports to the Autorité. A divestiture trustee may be empowered, if the parties miss the divestiture deadline, to sell the business, often at no minimum price, which creates a powerful incentive for the parties to complete the sale themselves. OECD comparative work on merger remedies underscores that trustee independence, clear mandates and adequate powers are decisive factors in whether remedies actually work in practice.

Designing an Effective Divestiture in France: Practical Steps

A divestiture only works if it produces a genuinely competitive standalone business acquired by a credible buyer. The following practical steps reflect how experienced teams approach divestiture design under French practice.

Scope and Buyer Selection

Define the divestiture perimeter precisely and defensibly. The perimeter should capture everything the business needs to compete, key contracts, personnel, IP, brands and customer relationships, without gratuitously stripping the retained group. Buyer suitability is equally critical: the Autorité will assess whether the proposed purchaser is independent of the parties, has the financial resources and industry expertise to operate the business, and will actually restore competition. Parties are well advised to identify a realistic pool of candidate buyers before committing to a divestiture package, because a remedy that cannot attract a viable purchaser is worthless.

Timing, Purchaser Approval and Data Room

Divestiture processes run on tight, regulator-supervised timetables. Parties typically have a defined period to find a buyer and sign a binding sale agreement, followed by Autorité approval of the purchaser before completion. Preparing a clean, comprehensive data room early accelerates the sale process and signals seriousness to both the regulator and prospective buyers. Building realistic milestones into the SPA, reflecting the divestiture period, the approval step and any first and second deadlines before a divestiture trustee is triggered, avoids the trap of committing to timelines that cannot be met.

Trustee Model and Trustee Terms

Where a divestiture is required, the trustee arrangement should be documented with care. A well-drafted trustee framework addresses the trustee’s independence, mandate, remuneration, reporting obligations, powers to run or sell the business, indemnification and replacement mechanics. The following illustrative clause shows a divestiture trustee appointment provision:

“Trustee Appointment. Within [10] business days of the Commitments Decision, the Parties shall propose to the Autorité de la concurrence for approval an independent Divestiture Trustee. The Divestiture Trustee shall (i) monitor the Parties’ compliance with the Divestiture Commitments; (ii) upon expiry of the First Divestiture Period, be irrevocably mandated to effect the sale of the Divestment Business at no minimum price to a Purchaser approved by the Autorité; and (iii) report to the Autorité at intervals of no less than [monthly]. The Parties shall indemnify the Divestiture Trustee against all liabilities arising from the proper performance of its mandate, save for gross negligence or wilful misconduct.”

This drafting reflects two essential features of merger remedies France: the trustee’s power to sell at no minimum price after the initial period, and the parties’ indemnity obligation. Both align the parties’ incentives toward completing the sale themselves before the trustee’s power crystallises.

Asset Carve-Out and Employee Transfer Under French Labour Law

Carve-out execution in France must account for the automatic transfer of employees. Under French labour law, the transfer of an autonomous business unit can carry employees with it, and works council or employee representative information and consultation obligations can materially affect timing. Deal teams should map affected employees, transitional service dependencies and any collective bargaining implications early, because these labour-law realities frequently determine how quickly a divestiture can complete.

Behavioural Commitments: Drafting, Monitoring and Enforcement Risks

Behavioural remedies France demand disciplined drafting because their value depends entirely on sustained compliance and enforceability. Poorly drafted commitments create years of monitoring friction and litigation exposure.

Typical Behavioural Clauses

Common behavioural commitments include obligations to supply key inputs to third parties on fair, reasonable and non-discriminatory terms; to maintain interoperability or access to a platform; or to refrain from bundling or tying that would foreclose rivals. The drafting must translate these principles into concrete, testable obligations. A supply commitment, for example, should specify the products covered, the pricing methodology, the duration, and the dispute resolution route where a customer alleges discrimination.

Monitoring, Periodic Reporting and Penalty Regimes

Monitoring is the backbone of behavioural remedies. A monitoring trustee typically receives periodic reports, audits compliance and flags breaches to the Autorité. The following illustrative clause shows a behavioural monitoring provision:

“Behavioural Monitoring. The Purchaser shall, for a period of [X] years from Completion, supply [Product] to any Eligible Customer on terms no less favourable than those offered to its affiliated undertakings. The Purchaser shall submit to the Monitoring Trustee a quarterly compliance report detailing all supply requests, terms offered and any refusals, together with supporting data. Any failure to comply shall entitle the Autorité to impose sanctions in accordance with the Code de commerce and, where the breach is material and persistent, to require conversion of this commitment into a structural remedy.”

Objective reporting obligations and a clear escalation path make the difference between an enforceable commitment and an aspirational one.

When Behavioural Remedies Fail

Behavioural remedies can fail when compliance erodes over time, when market conditions change, or when monitoring proves inadequate. The most robust packages build in conversion or divestiture triggers: if a behavioural commitment is materially breached or shown to be ineffective, the parties may be required to implement a structural fix instead. Anticipating this fallback in the SPA, and pricing it into the parties’ risk allocation, protects against the scenario where a conduct remedy unravels post-closing.

Clearance Conditions and SPA Drafting: Managing Filing Risk and Conditionality

The SPA is where clearance risk is allocated and remedies are operationalised. Getting the conditionality architecture right is central to any merger remedies France strategy.

Conditions Precedent Versus Undertakings

Deal teams must decide how to reflect regulatory clearance in the SPA. The most common approach makes clearance, including satisfaction of any conditions or commitments, a condition precedent to completion. Alternatively, parties may commit through covenants to use defined efforts to obtain clearance, including offering remedies. The choice of standard is heavily negotiated: buyers prefer flexibility to walk away if remedies become too onerous, while sellers seek certainty that the buyer will offer whatever remedies are necessary to close (“hell or high water” formulations). The middle ground typically caps the remedies a buyer must accept by reference to defined materiality thresholds.

Material Adverse Change and Reverse Break Fees

Where clearance risk is significant, sellers often negotiate a reverse break fee payable if the deal fails on regulatory grounds, compensating for the lost time and disruption of a busted transaction. Material adverse change provisions must be drafted with the remedies process in mind, for instance, clarifying whether the imposition of a divestiture constitutes an MAC. Aligning MAC definitions, efforts standards and break-fee triggers is essential to avoid contradictory outcomes when a remedy package emerges.

SPA Clause Bank for Remedies

A remedies-aware SPA should address, at a minimum:

• Regulatory efforts covenant. The agreed standard of effort each party must apply to secure clearance, including the offering of remedies.
• Remedy cap. The maximum scope of divestitures or commitments a buyer is obliged to accept before it may terminate.
• Trustee appointment. Machinery for proposing, approving and, if necessary, replacing monitoring and divestiture trustees.
• Implementation timetable. Milestones for filing, remedy negotiation, purchaser approval and divestiture completion, synchronised with the regulator’s periods.
• Indemnities and risk allocation. Responsibility for the cost and consequences of remedy implementation, including trustee fees and any shortfall on divestiture proceeds.

Practical Negotiation Positions for Buyers and Sellers

In remedies negotiation France, buyers generally resist open-ended obligations and press for defined caps, MAC protection and the right to terminate if remedies exceed agreed limits. Sellers push for strong efforts covenants, reverse break fees and tight completion timetables. Private equity buyers, sensitive to financing and holding-period constraints, often prioritise deal certainty and closing speed over remedy scope. A balanced SPA reconciles these positions with a clearly defined remedies cap and a proportionate reverse break fee, so that both sides understand precisely who bears clearance risk.

Interaction with FDI Screening in 2026: Sequencing, Overlaps and Mitigation

One of the defining features of merger remedies France in 2026 is the growing intersection with foreign investment screening. A transaction can require both competition clearance and FDI authorisation, and the two regimes must be managed in tandem.

FDI Regime Basics

France’s foreign investment control regime, administered by the Ministry for the Economy and Finance (through its Treasury directorate), requires prior authorisation for certain acquisitions by foreign investors in sensitive sectors touching national security, public order or strategic activities. Where an acquisition falls within the regime’s scope, the Minister can authorise it, subject it to conditions or prohibit it. These conditions, for example, undertakings to maintain strategic capabilities in France or to protect sensitive information, function as a parallel set of remedies distinct from competition commitments.

Timing and Procedural Overlaps With Merger Control

Competition review and FDI review run on separate timelines and answer to different authorities, but they can affect the same deal. A divestiture demanded by the Autorité might involve a strategic asset the Ministry wishes to keep in domestic hands; conversely, an FDI condition might constrain how a divestiture buyer is selected. Deal teams should identify both filings at the outset, understand the interaction between the standstill obligations, and plan for the possibility that one clearance conditions the other. Coordinating the two processes prevents contradictory commitments and reduces the risk of unexpected delay.

Practical Runbooks: Parallel Filings and Staged Remedies

Effective practice is to run parallel filings with a single coordinated strategy, ensuring that any remedy proposed to one authority is checked against the requirements of the other. Where sensitive or export-controlled data is involved, confidentiality protocols and clean-team arrangements are essential during both reviews. Staging remedies, sequencing divestiture and FDI undertakings so they reinforce rather than contradict each other, is often the difference between a clean dual clearance and a stalled transaction. The interaction of competition and FDI review is now a core dimension of designing merger remedies France that actually clear.

Case Studies: Autorité Decisions and Implications for Dealmakers

Autorité de la concurrence remedies decisions reinforce several lessons for deal teams, and practitioners should consult the precise decision pages published on the Autorité’s official site for the current position on any given sector.

• Structural fixes for concentrated local markets. Where a transaction produces high concentration in specific local or product markets, the Autorité has consistently favoured targeted divestitures over behavioural commitments, confirming that structural remedies remain the default for clear horizontal overlaps.
• Scrutiny of purchaser viability. Decisions emphasise that an approved buyer must be genuinely capable of competing, driving parties to identify credible purchasers early and to structure divestiture perimeters that produce standalone-viable businesses.
• Enforceable behavioural drafting. Where behavioural remedies have been accepted, the Autorité has required precise, measurable obligations with robust monitoring, underlining the risks of vague commitments.

Judicial review provides a further discipline on remedies practice: appeals against certain Autorité decisions may be brought before the Conseil d’État, which tests the proportionality and reasoning of imposed conditions, and the resulting jurisprudence shapes how remedies are designed and justified.

Practical Checklist and Negotiation Timeline for Deal Teams

The following sequence captures the workstream from signing through to remedy implementation:

1. Pre-filing. Assess merger control and FDI triggers; identify likely competitive concerns; scope potential divestiture perimeters and candidate buyers; agree the SPA remedies architecture (efforts standard, cap, break fee).
2. Filing. Submit competition and, where required, FDI notifications; establish clean-team and confidentiality protocols for both processes.
3. Remedies negotiation. Engage the Autorité on the remedy package; propose commitments proactively to retain drafting control; reconcile any FDI undertakings.
4. Trustee appointment. Propose monitoring and, where relevant, divestiture trustees for regulator approval; finalise trustee mandate and indemnities.
5. Implementation and monitoring. Execute hold-separate obligations; run the divestiture sale process; secure purchaser approval; comply with behavioural reporting.
6. Post-clearance. Complete divestiture within agreed periods; maintain ongoing behavioural compliance; manage trustee reporting until commitments expire.

For deal teams working across related structuring questions, the interplay between remedies and consideration mechanics is explored in the Global Law Experts guidance on Earn-outs in France, drafting & enforcement. Teams seeking specialist support can consult the M&A lawyers directory on Global Law Experts. Complementary practical resources include the France M&A practice area and further analysis on merger control and FDI screening in France.

Conclusion: Turning Merger Remedies France Into Deal Certainty

In 2026, merger remedies France are no longer a technical afterthought but a central determinant of whether a transaction completes on terms the parties can live with. The combination of an assertive Autorité de la concurrence, an active FDI regime and the exacting standards for divestiture viability and behavioural monitoring means that remedies must be anticipated, negotiated and documented with precision. Deal teams that treat remedy design as a core workstream, mapping perimeters, identifying viable buyers, structuring trustee mechanics and drafting SPA conditionality that fairly allocates clearance risk, will navigate the process far more successfully than those who react to regulator demands late.

The practical tools in this guide, from the comparison of remedy types to the illustrative clause examples and negotiation timeline, are intended to help practitioners convert regulatory complexity into executable deal terms.

This article is provided for general information only and does not constitute legal advice. Transactions raising merger control or foreign investment questions should be assessed with qualified counsel by reference to the specific facts.

Sources

1. Autorité de la concurrence
2. Légifrance, Code de commerce
3. European Commission, Mergers
4. EUR-Lex, Council Regulation (EC) No 139/2004
5. Ministère de l’Économie et des Finances, Foreign Investment Screening
6. Conseil d’État
7. OECD, Competition and Merger Remedies
8. Conseil National des Barreaux